Please ensure Javascript is enabled for purposes of website accessibility

Why TG Therapeutics Stock Exploded Higher Today

By George Budwell - Mar 6, 2017 at 1:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech struck gold with its lead drug candidate.

What happened

Shares of clinical-stage biotech TG Therapeutics (TGTX -4.97%) soared on Monday after the company announced that its experimental leukemia drug TG-1101 (ublituximab) hit the mark in a late-stage trial when used as part of a combination therapy that included AbbVie's (ABBV 1.93%) Imbruvica. As of 12:22 p.m. EST, the stock had gained 87%.

Perhaps most impressively, the combo's overall response rate was a whopping 80% in high-risk chronic lymphocytic leukemia patients, compared to 47% in patients receiving only Imbruvica. 

Illustration of blood cancer cells

Image source: Getty Images.

So what

The Street obviously wasn't a big believer in TG Therapeutics' lead drug candidate, given the company's small market cap of less than $300 million prior to today's news. Nonetheless, these late-stage results appear to be not only strong enough to warrant a regulatory approval, but perhaps make it a go-to therapy for this rare form of blood cancer in later line settings. 

Now what

According to the press release, TG Therapeutics is planning on presenting the trial's full data set at an upcoming scientific conference, and discussing the possibility of an accelerated regulatory filing with the Food and Drug Administration as soon as possible.

Before either of these events take place, however, investors shouldn't be too surprised if TG is gobbled up by a larger pharma. In fact, AbbVie may come calling in order to protect and bolster its emerging hematology franchise. Cancer drugs, after all, are highly sought-after products in the pharma industry, especially ones with unusually strong efficacy profiles like ublituximab.

Having said that, TG's last stated cash position of around $60 million leaves much to be desired -- which suggests the company will probably use this spike in its share price to raise funds. So, investors that missed this monstrous liftoff may be able to buy a piece of this intriguing growth story at a reduced price within the next few days -- that is, after a largish secondary offering. Until then, it may be wise to simply sit back and wait for a better entry point.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

TG Therapeutics Stock Quote
TG Therapeutics
TGTX
$4.40 (-4.97%) $0.23
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$152.34 (1.93%) $2.89

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.